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o r i g i n a l a r t i c l e
A Population-Based Investigation of Invasive
Vancomycin-Resistant Enterococcus Infection
in Metropolitan Atlanta, Georgia, and Predictors of Mortality
Bernard C. Camins, MD, MSCR; Monica M. Farley, MD; John J. Jernigan, MD;
Susan M. Ray, MD; James P. Steinberg, MD; Henry M. Blumberg, MD
background. Vancomycin-resistant Enterococcus organisms (VRE) have emerged as common nosocomial pathogens, but few population-
based data are available on the impact of invasive VRE infections.
methods. We assessed the incidence of invasive VRE infections and predictors of mortality among patients identified during prospective,
population-based surveillance performed in the metropolitan statistical area (MSA) of Atlanta, Georgia.
results. From July 1997 through June 2000, a total of 192 patients who resided in the Atlanta MSA developed an invasive VRE infection,
for a rate of 1.57 cases per 100,000 person-years. The incidence of invasive VRE disease significantly increased from 0.91 cases per 100,000
person-years during the first year of the study to 1.73 cases per 100,000 person-years during the third year of the study ( ). RatesP ! .001
of invasive VRE infection were significantly higher among African American patients than white patients (2.59 vs 0.70 cases per 100,000
person-years; ). Blood was the most common sterile site from which VRE was recovered (161 [83%] of 193 isolates), followed byP ! .001
deep surgical sites (17 [9%]), peritoneal fluid (10 [5%]), pleural fluid (3 [2%]), and cerebrospinal fluid (1 [0.5%]). In multivariate analysis,
a Charlson comorbidity index of 5 or greater, previous receipt of antibiotic therapy, having 2 or more sets of blood cultures positive for
VRE, and receipt of central parenteral nutrition were independent predictors of mortality, whereas receipt of an antibiotic with in vitro
activity against the VRE isolate was associated with a decreased risk of mortality. Molecular typing revealed 38 different pulsed-field gel
electrophoresis patterns, but the 2 most common pulsed-field gel electrophoresis types were found at 3 Emory University–affiliated hospitals.
conclusions. The incidence of invasive VRE infection significantly increased in the Atlanta MSA during the 3-year study period, with
significant racial disparities detected. Receipt of an antimicrobial agent with in vitro activity against VRE was associated with a lower
mortality rate. Molecular typing results demonstrated polyclonal emergence of VRE in Atlanta.
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Enterococcus species have emerged as important nosocomial
pathogens, with an increasing prevalence of antibiotic resis-
tance.1,2 The Centers for Disease Control and Prevention’s
National Nosocomial Infections Surveillance System has re-
ported a steady increase in the prevalence of vancomycin
resistance among Enterococcus isolates during the past de-
cade.3 Infections due to vancomycin-resistant enterococci
(VRE) have been reported to be associated with longer hos-
pital stays, increased mortality, and higher costs than infec-
tions with vancomycin-susceptible enterococci.4-6 Treatment
failures are also more likely among patients with VRE infec-
tion.7 In the United States, VRE has been reported almost
exclusively in patients with a past history of exposure to
healthcare settings.8-10
VRE can cause invasive infection and colonization. Risk
factors for VRE colonization include antecedent treatment
with intravenous or oral vancomycin, cephalosporin antibi-
otics, fluoroquinolones, and antimicrobials with antianaero-
bic coverage.11-19 Risk factors for invasive VRE infection, such
as bacteremia, have been reported to include receipt of van-
comycin and prior receipt of other antibiotics (including
those that have antianaerobic activity), hematologic malig-
nancy,20 corticosteroid use,10 renal failure, neutropenia, hy-
peralimentation, a history of gastrointestinal procedure, and
prolonged hospital stay.18,21 Patients with VRE infection often
have more comorbidities than do other patients in the hospi-
tal.10,20 Previous studies have shown that vancomycin re-
sistance,17,22,23 hematologic malignancy,10 more severe ill-
ness,10,18,23-25 cephalosporin and antianaerobic antimicrobial
use,23 and older age25 are independent predictors of mor-
tality among patients infected with VRE.
Results from these studies are hard to generalize to all
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patients, because they often focus on a select group of pa-
tients, such as those with malignancy or those who have
undergone organ transplantation. In addition, nearly all re-
ports on VRE infection have been hospital-based studies from
a single center.5,6,8,18,20-22,24-31 Similarly, molecular epidemio-
logic studies of VRE have been usually limited to 1 or 2
institutions as part of outbreak investigations, and in most
reports, hospital outbreaks involved oligoclonal spread of
VRE.3 Rates of VRE infection in a defined community, such
as a metropolitan area, have not, to our knowledge, been
previously described.
The purpose of our study was to describe the clinical and
molecular epidemiology of invasive VRE infections in the 20-
county metropolitan statistical area (MSA) of Atlanta, Geor-
gia. The objectives of our population-based study were as
follows: (1) to determine the incidence of invasive VRE in-
fections, (2) to determine the clinical characteristics of pa-
tients with VRE infections, (3) to determine the predictors
for VRE-related mortality, and (4) to study the molecular
epidemiology of VRE infection.
methods
Prospective, population-based, laboratory-based surveillance
was performed. VRE isolates were collected from 43 hospital
and reference laboratories in the Atlanta MSA as part of the
Active Bacterial Core Surveillance Program of the Georgia
Emerging Infections Program. Initial case reports and data
on isolates were obtained from the microbiology laboratories
through a review of all VRE-positive cultures of invasive spec-
imens. Laboratory audits at all laboratories occurred every 6
months during the study period to evaluate reporting ac-
curacy and identify cases not originally reported. The method
used for prospective collection of isolates has been described
elsewhere.32-34 At-risk persons were the entire population of
the 20-county Atlanta MSA. The population was 3,746,059
persons in 1998 and increased to 4,112,198 in 2000. Data
were collected on VRE isolates recovered from normally ster-
ile body sites between July 1, 1997, and June 30, 2000. De-
mographic and clinical data were abstracted from the patients’
medical records. This study was approved by the Emory Uni-
versity and the Georgia Department of Human Resources
institutional review boards and the Grady Memorial Hospital
Research Oversight Committee.
Definitions
VRE infection was classified as nosocomial if recovery of the
isolate occurred greater than 48 hours after admission. It was
classified as a healthcare-associated infection if recovery of
the isolate occurred within 48 hours after admission and the
patient was admitted to a hospital for at least 2 days within
the past 90 days or resided in a nursing home or a long-term
care facility before the current admission.36 Invasive VRE in-
fection was defined as recovery of VRE from the blood, cere-
brospinal fluid, pleural fluid, pericardial fluid, synovial fluid,
and sterile surgical sites (ie, not from open wounds). Thirty-
day in-hospital mortality was defined as death that occurred
within 30 days after recovery of an invasive VRE isolate. The
site of isolation was defined as the first sterile site from which
the VRE isolate was recovered. End-stage renal disease (ESRD)
was defined as the need for dialysis before or during the
current admission. Chronic renal insufficiency was defined
as a creatinine level of 144.4 mmol/L (1.6 mg/dL) or higher,
without the need for dialysis, before the admission. Previous
antibiotic treatment was defined as receipt of any antimicro-
bial agent during the period before the date that the culture-
positive specimen was collected. Polymicrobial bloodstream
infection was defined as the recovery of other pathogens (bac-
terial or fungal) from the same blood culture that was positive
for VRE. Severity of illness was determined using the Charlson
comorbidity index.35
Microbiological Analysis and Molecular Typing
Species identification of enterococcal isolates and antimicro-
bial susceptibility testing to identify vancomycin-resistant iso-
lates were performed at the local laboratories. For the 120
VRE isolates available for analysis, species identification was
verified using the API-20 Strep Identification System (bioMe´-
rieux) at our own epidemiology laboratory. For the 73 re-
maining VRE isolates, species identification was based on
findings of commercial methods available at the local labo-
ratory. Pulsed-field gel electrophoresis (PFGE) was performed
in our laboratory according to the methods described by
Bannerman et al.,37 using Chef DR II (Bio-Rad Laboratories)
with alternating switch times of 20 seconds and 1 second for
24 hours at 14C. The DNA plugs were digested with SmaI
restriction enzymes for 18 hours. Computer-assisted strain
analysis was performed with Bionumerics software (Applied
Maths). Cluster analysis was performed with unweighted pair
group averages. Visual analysis was performed according to
the criteria of Tenover et al.38
Statistical Analysis
The x2 test for trend was used to compare infection rates
(incidence densities) by year. The Student t test or the Wil-
coxon rank sum test was used to analyze continuous variables,
depending on the validity of the normality assumption. The
Mantel-Haenszel x2 test was used to analyze categorical var-
iables and proportions. A 2-sided P value of less than .05 was
considered statistically significant. A case-control method was
used to assess predictors of 30-day in-hospital mortality. Cases
were patients with invasive VRE infection who died within
30 days after the initial recovery of a VRE isolate from a
sterile body site, whereas controls were patients with invasive
VRE infection who were alive 30 days after the diagnosis of
VRE infection. Multivariate analysis was performed with
backward stepwise elimination logistic regression analysis.
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table 1. Demographic Characteristics of Patients With Invasive
Vancomycin-Resistant Enterococcus (VRE) Infection Who Were
Cared for in the Metropolitan Statistical Area (MSA) of Atlanta,
Georgia
Characteristic





Resident of the Atlanta MSA 156 (81)
Race




Native American 1 (0.5)
Unknown 5 (2.6)
Age, years, mean  SD 54.43  16.47
Residence before admission
Home 141 (73)
Nursing home 17 (9)
Personal care home 18 (9)
Unknown 16 (9)
Time of previous hospitalization
Previous 6 months 100 (52)
Previous year 10 (5)




note. Data are number (%) of patients, unless otherwise indicated. MSA,
metropolitan statistical area.
a VRE isolates were more likely to be recovered from teaching institutions
(relative risk, 1.71 [95% confidence interval, 1.32-2.21]; ).P ! .001
figure 1. Incidence rate of invasive vancomycin-resistant En-
terococcus infection during the 3-year period. Year 1: July 1, 1997,
through June 30, 1998; year 2: July 1, 1998, through June 30, 1999;
and year 3: July 1, 1999, through June 30, 2000.
Variables included in the multivariate analysis were those
found to be significant predictors of 30-day mortality in uni-
variate analysis and factors that had biologic plausibility, such
as receipt of antimicrobial agents; demographic data, such as
sex, age, and race/ethnicity, were also included in the logistic
regression models.
Two different logistic regression models were created. The
first model included all of the individual risk factors except
the variables representing the Charlson comorbidity index.
The second model was created to determine whether the
Charlson comorbidity index is a good predictor of mortality
among patients with invasive VRE infection. Any risk factor
that was part of the Charlson comorbidity index (ie, acute
renal failure, ESRD, malignancy, and receipt of chemother-
apy) was excluded from the second logistic regression model.
Twenty-three cases were excluded from the multivariate anal-
ysis because of insufficient data on outcomes or risk factors.
Potential effect modification among race, age, and other risk
factors was investigated. No significant interactions were de-
tected between any of the variables. Data analyses were per-
formed with SAS software, version 9.0 (SAS Institute). A P
value of .05 or less was considered statistically significant.
results
During the 3-year study period, 192 patients cared for in the
Atlanta MSA had invasive VRE infection. Demographic char-
acteristics of these patients are given in Table 1. A total of
156 patients (81%) were residents of the 20-county Atlanta
MSA. The remaining 36 patients (23%) resided outside the
20-county Atlanta MSA but were admitted to hospitals within
the MSA. These patients were more likely to be transplant
recipients (unadjusted odds ratio [uOR], 4.2 [95% confidence
interval {CI}, 1.2-14.8]; ) or admitted to a tertiaryPp .02
care academic medical center (uOR, 7.5 [95% CI, 3.2-17.5];
). No other differences were found between the MSAP ! .001
residents and the non-MSA residents in terms of comorbid
illnesses or outcomes. The incidence of invasive VRE infection
among the 192 patients was 1.29 cases per 100,000 person-
years during the 3-year study period. The incidence increased
from 0.77 cases per 100,000 person-years in year 1 to 1.60
cases per 100,000 person-years in year 3 of the study (July
1999 through June 2000) ( ) (Figure 1).Pp .001
Of patients cared for in the Atlanta MSA, the mean annual
incidence rates among African American patients were sig-
nificantly higher than those among white patients (2.59 vs
0.70 cases per 100,000 person-years; ). During the 3-P ! .001
year study period, the incidence of invasive VRE infections
increased significantly among African American patients,
from 1.85 per 100,000 person-years in year 1 of the study to
3.61 per 100,000 person-years in year 3 ( ), but notP ! .001
among white patients (Table 2 and Figure 1). African Amer-
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table 2. Rates of Invasive Vancomycin-Resistant Enterococcus
(VRE) Infection Among Residents of the Metropolitan Statistical








Year 1a 0.77 1.85 0.53 !.01
Year 2b 1.01 2.10 0.77 !.01
Year 3c 1.60 3.61 0.81 !.01
Overall 1.29 2.59 0.70 !.01
P .001 !.001 .21
a July 1, 1997, through June 30, 1998.
b July 1, 1998, through June 30, 1999.
c July 1, 1999, through June 30, 2000.
figure 2. Species identification of 193 vancomycin-resistant En-
terococcus isolates recovered from 192 patients. Vancomycin-resistant
Enterococcus faecium and vancomycin-resistant Enterococcus faecalis
were both isolated from a single patient.
ican patients were more likely than white patients to be female
(uOR, 2.4 [95% CI, 1.3-4.4]; ), have a diagnosis ofPp .006
acquired immunodeficiency syndrome (uOR, 7.0 [95% CI,
1.6-31.7]; ), and be admitted to a teaching hospitalPp .004
(uOR, 8.4 [95% CI, 1.9-7.0]; ). No race-based dif-P ! .001
ferences in mortality rates were found.
Two distinct VRE species (Enterococcus faecium and En-
terococcus faecalis) were recovered from 1 patient. Of the 193
isolates recovered from the 192 patients, E. faecium was the
most common VRE species recovered (161 isolates [83%]),
followed by E. faecalis (12 isolates [6%]) (Figure 2). Thirteen
isolates (7%) were not speciated by the participating labo-
ratory, and these isolates were not available for further testing
in our laboratory. Blood was the most common sterile site
from which VRE was isolated (161 isolates [83%]), followed
by deep surgical sites (17 [9%]), peritoneal fluid (10 [5%]),
pleural fluid (3 [2%]), and cerebrospinal fluid (1 [0.5%]).
One hundred forty-three (74%) of 192 patients with an
invasive infection had VRE isolated more than 48 hours after
admission (ie, representing nosocomial infection). Of the re-
maining 49 patients, all of whom had VRE isolated from culture
within 48 hours after admission, 35 (71%) were considered to
have healthcare-associated infections; 9 of these 35 patients
were transferred from other hospitals, 10 resided in a nursing
home or long-term care facility, and 16 were hospitalized within
90 days before the current admission. Therefore, at least 93%
of the infections could be considered healthcare associated, and
we suspect that the remaining 7% would also have been clas-
sified as healthcare associated if complete medical records were
available for the affected patients. Data on demographic and
clinical characteristics, diseases and conditions, and treatments
and procedures are presented in Table 3.
The crude mortality rate for patients with invasive VRE
infection was 43% (82 of 192) and was not significantly dif-
ferent from that for individuals with bacteremia alone (47%
[75 of 161]; ). The crude mortality rate for patientsPp .45
who did not receive an antimicrobial that had in vitro activity
against VRE was 46% (39 of 85). The risk factors for 30-day
in-hospital mortality in univariate analysis were as follows:
ESRD, acute renal failure without the need for dialysis, receipt
of chemotherapy, receipt of antimicrobial treatment before
recovery of the VRE isolate, presence of a central venous
catheter, Charlson comorbidity index of 4 or greater, receipt
of central parenteral nutrition, diagnosis of candidemia in-
dependent of the VRE infection, VRE infection in the blood-
stream instead of another invasive site, and, for persons with
a bloodstream infection, and presence of 2 or more sets of
blood cultures positive for VRE (Tables 3 and 4).
In the first logistic regression model, independent predic-
tors of 30-day in-hospital mortality included receipt of che-
motherapy, previous receipt of antibiotic therapy, ESRD or
acute renal failure at the time of infection, and having 2 or
more sets of blood cultures positive for VRE. Receipt of an
antimicrobial with in vitro activity against the VRE isolate
was protective against 30-day in-hospital mortality (Table 5).
In the second logistic regression model, in which comorbid-
ities already included in the Charlson comorbidity index were
removed from analysis, a Charlson comorbidity index of 5
or greater, previous receipt of antibiotic therapy, having 2 or
more sets of blood cultures positive for VRE, and receipt of
central parenteral nutrition were independent predictors of
30-day in-hospital mortality (Table 5). As in the first model,
receipt of an antimicrobial with in vitro activity against the
VRE isolate was protective against 30-day in-hospital mortality.
Molecular Analysis
A total of 66 distinct PFGE patterns were noted among the
109 vancomycin-resistant E. faecium isolates available for mo-
lecular typing. Eleven vancomycin-resistant E. faecium isolates
that had an identical PFGE pattern (type A) were recovered
from patients receiving care at 5 different hospitals, and van-
comycin-resistant E. faecium isolates with another PFGE pat-
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table 3. Baseline Characteristics of Patients With Invasive Vancomycin-Resistant Enterococcus (VRE) Infection










Demographic or clinical characteristic
Male sex 107 (56) 41/107 (38) 36/85 (42) 0.85 (0.47-1.51) .57
Charlson comorbidity index x4 68 (35) 35/68 (51) 42/124 (34) 2.07 (1.13-3.79) .02
x2 sets of VRE-positive blood cultures 47 (24) 27/47 (57) 50/145 (34) 2.56 (1.31-5.02) .005
Disease or condition
Diabetes mellitus 42 (22) 15/42 (36) 62/141 (44) 0.71 (0.35-1.44) .34
COPD 25 (13) 9/25 (36) 68/157 (43) 0.74 (0.31-1.77) .49
ESRD 54 (28) 31/54 (57) 46/129 (36) 2.43 (1.27-4.65) .004
ARF 39 (20) 27/39 (69) 50/142 (35) 4.14 (1.93-8.87) !.001
CRI 24 (13) 11/24 (46) 66/158 (42) 1.18 (0.50-2.80) .71
Liver disease 24 (13) 13/24 (54) 64/158 (41) 1.74 (0.73-4.12) .21
Malignancy 44 (23) 24/44 (55) 53/137 (39) 1.91 (0.96-3.78) .06
Neutropenia 48 (25) 26/48 (54) 47/111 (42) 1.61 (0.82-3.18) .17
HIV infection 23 (12) 12/23 (52) 65/169 (38) 1.75 (0.73-4.19) .39
AIDS 19 (10) 9/19 (48) 68/173 (39) 1.39 (0.54-3.60) .50
Trauma 10 (5) 3/10 (30) 73/170 (43) 0.57 (0.14-2.28) .42
Bacteremia
Monomicrobial 51 (27) 25/51 (49) 52/130 (40) 1.44 (0.75-2.77) .27
Polymicrobial 69 (36) 32/69 (46) 45/123 (37) 1.50 (0.82-2.73) .19
Candidemia 26 (14) 16/26 (62) 61/155 (39) 2.47 (1.05-5.79) .03
Bloodstream infection 161 (84) 70/161 (43) 7/31 (23) 1.44 (1.07-6.47) .03
Treatment or procedure
Chemotherapy 28 (15) 19/28 (68) 58/153 (38) 3.46 (1.47-8.15) .003
Transplantation 11 (6) 6/11 (55) 71/170 (42) 1.67 (0.49-5.70) .41
Surgery 77 (40) 31/77 (40) 45/103 (44) 0.87 (0.48-1.58) .65
Central venous access 139 (72) 65/139 (47) 11/39 (28) 2.24 (1.03-4.84) .04
Total parenteral nutrition 79 (41) 43/79 (54) 34/102 (33) 2.39 (1.31-4.37) .005
Previous antibiotic treatment 151 (79) 72/151 (48) 3/20 (15) 5.16 (1.45-18.36) .006
note. Data are no. (%) or proportion (%) of patients. The total for each risk factor may not equal 192 patients because of
incomplete information. AIDS, acquired immunodeficiency syndrome; ARF, acute renal failure; CI, confidence interval; COPD,
chronic obstructive pulmonary disease; CRI, chronic renal insufficiency; ESRD, end-stage renal disease; HIV, human immuno-
deficiency virus; uOR, unadjusted odds ratio.
tern (type B) were recovered from patients at 4 different
hospitals. Type A and type B isolates were recovered from
patients at 3 of the Emory University–affiliated teaching hos-
pitals (house staff rotate among the hospitals).
Ten of 12 vancomycin-resistant E. faecalis isolates were also
available for molecular typing. A total of 6 distinct PFGE
patterns were noted among E. faecalis isolates; 5 isolates had
an identical PFGE type and were recovered from a single
institution. The other 5 E. faecalis isolates had distinct PFGE
types.
discussion
VRE is a multidrug-resistant pathogen, and infection and
colonization with VRE is generally associated with healthcare
contact. Previous studies have been institution based, and few
data on the incidence of infection in a community are
available.5,6,18,20-22,24,25,28-30,39-41 No prior molecular epidemi-
ologic analysis has been performed in a population-based
study. Our population-based study demonstrated a significant
increase in the incidence of invasive VRE infection in the
Atlanta MSA (from 0.77 to 1.60 per 100,000 person-years)
during the 3-year study period. VRE isolates were more likely
to be associated with teaching hospitals than with nonteach-
ing hospitals, a finding that was only reported in 1 other
study.42
Our study found significantly higher rates of invasive VRE
infection among African American patients, compared with
white patients (2.59 vs. 0.70 infections per 100,000 person-
years; relative risk, 3.70). This racial disparity has not been
previously reported for invasive VRE infections but has been
described in a population-based study on invasive pneu-
mococcal disease.43 The reasons for the higher rates of invasive
VRE infection among African American patients treated in
the Atlanta MSA are not entirely clear, but we speculate that
this is related to higher rates of chronic diseases, such as
ESRD, among African American patients. Higher rates of
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table 4. Continuous Variables and Their Association With 30-Day In-Hospital Mortality Among










Age, years, mean  SD 54.43  16.47 52.34 49.77 .28
Charlson comorbidity index, mean  SD 3.29  2.41 3.97 2.79 .002
Defined daily dose of antibiotic, median 20 (0-246) 99.32 81.23 .02
Length of stay, days, median 33 (1-228) 88.69 100.14 .16
Time to infection, days, median 14 (0-131) 110.73 84.18 .001
table 5. Multivariate Analyses of Risk Factors for Invasive Vancomycin-Resis-
tant Enterococcus (VRE) Infection, According to the Exclusion (Model 1) and
Inclusion (Model 2) of the Charlson Comorbidity Index
Independent predictor aOR (95% CI) P
Model 1a
Chemotherapy 5.6 (1.9-16.4) .002
Previous antibiotic use 5.5 (1.3-23.6) .02
End-stage renal disease 4.1 (1.7-9.3) .001
x2 sets of VRE-positive blood cultures 3.95 (1.6-9.8) .003
Acute renal failure 3.4 (1.45-8.0) .005
Treatment with antimicrobial active against VREb 0.33 (0.14-0.77) .01
Model 2c
Charlson comorbidity index x5 5.2 (2.2-12.4) !.001
Previous antibiotic use 4.1 (1.0-16.9) .047
x2 sets of VRE-positive blood cultures 3.5 (1.4-8.3) .006
Receipt of central parenteral nutrition 3.1 (1.5-6.7) .003
Age x65 years 2.1 (0.97-4.7) .06
Treatment with antimicrobial active against VREb 0.45 (0.20-0.996) .045
note. aOR, adjusted odds ratio; CI, confidence interval.
a The following variables were also included in the backward stepwise logistic regression
model but were eliminated from the final model: age, race, sex, receipt of central parenteral
nutrition, presence of candidemia, site of infection, and presence of a central venous catheter.
b Receipt of any antimicrobial agent with in vitro activity against the VRE isolate (eg,
ampicillin, chloramphenicol, linezolid, and quinupristin-dalfopristin).
c Any risk factor that was part of the Charlson comorbidity index (ie, acute renal failure,
ESRD, malignancy, and receipt of chemotherapy) was excluded from model 2. The following
variables were also included in the backward stepwise logistic regression model but were
eliminated from the final model: race, sex, presence of candidemia, primary site of infection,
and presence of a central venous catheter.
ESRD among African American patients have been reported
elsewhere.44,45 Having ESRD would necessitate more fre-
quent contact with healthcare institutions, including in-
patient facilities.
Blood was the most common sterile site from which VRE
was recovered. This finding is not surprising, because Entero-
coccus organisms have been reported to be the second46 and
third47 most common pathogens isolated from patients with
bloodstream infections. In our study, E. faecium was the most
common species of VRE isolated, followed by E. faecalis. Van-
comycin-resistant Enterococcus gallinarum and Enterococcus
durans were also recovered from a few patients but accounted
for less than 5% of VRE isolates. Only 1 multicenter study
on enterococcal bacteremia provided data on the species of
the VRE isolates recovered and found a distribution similar
to that observed in our study.10 Two other multicenter studies
did not provide any data on speciation.7,42
The 30-day in-hospital mortality rate for all patients with
an invasive VRE infection was 40%. This crude mortality rate
is 37%-76% among patients with VRE bacteremia5,6,17,18,20,22,
23,25,28,30,48 reported from single-institution studies and similar
to that reported for Candida bloodstream infections.49 The
Charlson comorbidity index was found to be predictive of
30-day in-hospital mortality on both univariate and multi-
variate analyses. The Charlson comorbidity index may be a
good measure of severity of illness, because it was found to
have the highest adjusted OR (aOR; 5.2) for 30-day in-hos-
pital mortality. The following risk factors included in the
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Charlson comorbidity index were also found to be indepen-
dent predictors for mortality: receipt of chemotherapy, a sur-
rogate marker for malignancy (aOR, 5.6); ESRD (aOR, 4.1);
and acute renal failure at the time of diagnosis (aOR, 3.4).
Other independent predictors of mortality found in both lo-
gistic regression models were history of antibiotic therapy
(aOR, 5.5) and having multiple sets of blood cultures positive
for VRE (aOR, 4.0). Receipt of central parenteral nutrition
(aOR, 3.1) was also an independent predictor of mortality in
the second logistic regression model.
Our study was not designed to assess attributable mortality
associated with invasive VRE infection. However, the finding
that multiple positive blood cultures (compared with recovery
of VRE from a single culture) were an independent predictor
of mortality may be a surrogate for differentiating between
skin or catheter colonization versus a true VRE bloodstream
infection and suggests that VRE infection may have been the
cause of mortality in many cases. Previous antibiotic therapy
may have also been a surrogate for severity of illness in this
study, and this finding suggests that the Charlson comorbidity
index is not a complete measure of severity of illness. We
investigated several risk factors that are not accounted for in
the Charlson comorbidity index. Receipt of chemotherapy,
as opposed to just having an active malignancy, was found
to be an independent risk factor for mortality after an invasive
VRE infection. Patients with malignancies who receive che-
motherapy are likely to be more immunocompromised than
patients with malignancies who are not receiving chemo-
therapy. Although acute renal failure and receipt of hemo-
dialysis have been previously reported as risk factors for VRE
colonization50 and infection,21 they have not been previously
reported as independent predictors of VRE-related mortality.
A Charlson comorbidity index of 4 or greater, which is
indicative of severe illness, was predictive of mortality after
invasive VRE infection. The association between more-se-
vere illness and mortality among patients with VRE infec-
tion is consistent with findings from previously published
studies.7,10,18,20,23-25 Although Acute Physiology and Chronic
Health Evaluation II scores have been used to control for
severity of illness in some studies, we opted to use the Charl-
son comorbidity index,35 since we were unable to collect all
the information required to accurately assign Acute Physi-
ology and Chronic Health Evaluation II scores to all patients.
The use of the Charlson index as a measurement of illness
severity has been validated in a cohort of patients with Staph-
ylococcus aureus bacteremia51 but has not been previously used
in a study that involved a cohort of patients with invasive
VRE infection.
Multivariate analysis revealed that receipt of an antimicro-
bial agent with in vitro activity against VRE was associated
with a reduced risk of mortality. This finding suggests that
treatment of invasive VRE infections is an important factor
in preventing mortality. Our study is one of the few studies
that has accounted for treatment modalities in the multivar-
iate analyses.10,52 Because our study was performed during
1997-2000, most of the patients with VRE bacteremia or in-
vasive infection were treated with chloramphenicol or quin-
upristin-dalfopristin. Antimicrobials active against resistant
gram-positive bacteria, including VRE, such as linezolid, dap-
tomycin, and tigecycline, were not approved by the Food and
Drug Administration at the time of the study and therefore
were not commonly used. Linezolid was only available through
compassionate use during the study period, and only 1 patient
included in our study received it. The clinical efficacy of
chloramphenicol in treating VRE infection has been de-
bated.28 However, our study shows that, after adjusting for
other risk factors, treatment with any active agent against
VRE was protective against 30-day in-hospital mortality. Pa-
tients who were treated with any agent with in vitro activity
against the VRE isolate were pooled into 1 group, because
there would have been too few patients receiving each specific
treatment to arrive at a meaningful conclusion.
Molecular typing studies revealed a large number of dis-
tinct clones of VRE. A total of 66 different PFGE types were
found among the E. faecium isolates, indicating the emergence
of a great deal of genetic heterogeneity among VRE in the
Atlanta MSA. The 2 most common PFGE patterns (types A
and B) were recovered from patients from at least 4 different
hospitals, 3 of which were Emory University–affiliated teach-
ing hospitals. Introduction of these strains into these insti-
tutions could have occurred because of transfer of patients
among institutions or, potentially, because of carriage by per-
sonnel (eg, house staff or faculty physicians) who rotate
among the Emory University–affiliated hospitals. This poly-
clonal spread of VRE in the Atlanta MSA is consistent with
other reports that have shown that the polyclonal prolifera-
tion of VRE is common within single institutions.12,48,53,54
Our study has a few limitations. The isolation of VRE from
a single set of blood cultures may in some cases have rep-
resented colonization rather than infection. This approach
may account for the finding that isolation of VRE from 2 or
more sets of blood cultures was an independent predictor for
in-hospital mortality, although persistent or longer courses
of bacteremia could also reflect enhanced immunosuppres-
sion among some patients. This study also underscores the
importance of appropriate treatment with an agent active
against VRE, because the mortality rate for the 85 patients
who did not receive an active agent was still high at 46%.
We were also unable to perform our own analysis on every
isolate, so vancomycin resistance and species identification
were not verified in 38% of the cases. Finally, the study period
occurred before the introduction of newer agents (eg, line-
zolid and daptomycin) for the treatment of VRE infection.
Further studies are needed to assess the impact of these newer
agents on outcome and mortality.
In summary, to our knowledge, this is the first population-
based study of invasive VRE infection that included molecular
analysis. Our study showed an increase in the incidence rate
of invasive VRE infections (from 0.77 to 1.60 per 100,000
person-years) during the 3-year study period and significantly
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higher rates of infection among African American patients
compared with white patients, which may reflect higher in-
cidence of some chronic diseases (eg, ESRD) in the former
group. Although African American persons constituted only
27% of the population in the Atlanta MSA during the study
period, most cases of invasive VRE infection occurred in this
group. VRE infection was overwhelmingly healthcare asso-
ciated and was also associated with a high crude mortality
rate. Risk factors for mortality after VRE infection included
receipt of chemotherapy, ESRD, previous receipt of antibiotic
therapy, multiple VRE-positive blood cultures, and acute re-
nal failure. Treatment with an antimicrobial agent active
against VRE was associated with reduced mortality and em-
phasizes the need for prompt treatment of patients with in-
vasive VRE infection. Molecular typing results demonstrated
polyclonal emergence of VRE in the Atlanta MSA, although
interhospital spread was noted among several university-af-
filiated teaching hospitals.
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